Literature DB >> 35762799

Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.

Seongman Bae1,2, Eun Sil Kim1,2, Hee Seung Kim1,2, Eunmi Yang1,2, Hyemin Chung1,2, Yun Woo Lee1,2, Jiwon Jung1, Min Jae Kim1, Yong Pil Chong1, Sung-Han Kim1, Sang-Ho Choi1, Sang-Oh Lee1, Yang Soo Kim1,2.   

Abstract

Although several clinical variables have been reported as risk factors for recurrence of Staphylococcus aureus infection, most studies have not considered competing risk events that may overestimate the risk. In this study, we performed competing risk analysis to identify risk factors related to 90-day recurrence in patients with S. aureus bacteremia (SAB) using a large cohort data from a single tertiary hospital in South Korea. All adults who experienced SAB during admission were prospectively enrolled from August 2008 to December 2019. After the day of the first positive blood culture, recurrence and all-cause mortality were assessed for 90 days. Recurrence was defined as a development of symptoms or signs of infection with or without repeated bacteremia after >7 days of negative blood culture and clinically apparent improvement. Subdistribution hazard ratios (sHR) for recurrence and all-cause mortality were estimated using Fine and Gray models. Of 1,725 SAB patients, including 885 cases (51.3%) of methicillin-resistant S. aureus (MRSA) bacteremia, 85 (5.0%) experienced recurrence during the study period. In a multivariate Fine and Gray regression model, the presence of a vascular graft (subdistribution HR [sHR], 3.48; 95% confidence interval [CI], 1.90-6.40), nasal MRSA carriage (sHR, 2.10; 95% CI, 1.28-3.44), methicillin resistance (sHR, 1.69; 95% CI, 1.00-2.84), and rifampicin resistance (sHR, 2.20; 95% CI, 1.12-4.33) were significantly associated with 90-day recurrence. In a large cohort of SAB patients with a high prevalence of MRSA, indwelling vascular graft, nasal MRSA carriage, methicillin resistance, and rifampicin resistance were potential risk factors for recurrence of S. aureus infection.

Entities:  

Keywords:  Staphylococcus aureus; methicillin resistance; recurrence; rifampicin resistance

Mesh:

Substances:

Year:  2022        PMID: 35762799      PMCID: PMC9295554          DOI: 10.1128/aac.00126-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  46 in total

1.  Therapeutic outcomes of hematogenous vertebral osteomyelitis with instrumented surgery.

Authors:  Ki-Ho Park; Oh-Hyun Cho; Yu-Mi Lee; Chisook Moon; Seong Yeon Park; Song Mi Moon; Jung Hee Lee; Ji Seon Park; Kyung Nam Ryu; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Mi Suk Lee; Yang Soo Kim; Jun Hee Woo; In-Gyu Bae
Journal:  Clin Infect Dis       Date:  2015-02-06       Impact factor: 9.079

2.  Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Longzhu Cui; Maria Kapi; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  Association of intracellular Staphylococcus aureus with prognosis in chronic rhinosinusitis.

Authors:  Judy Ou; Amanda Drilling; Deepti Singhal; Neil C-W Tan; Deanna Wallis-Hill; Sarah Vreugde; Alkis J Psaltis; Peter-John Wormald
Journal:  Int Forum Allergy Rhinol       Date:  2016-04-15       Impact factor: 3.858

4.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

5.  The dynamic changes of dominant clones of Staphylococcus aureus causing bloodstream infections in the European region: results of a second structured survey.

Authors:  H Grundmann; L M Schouls; D M Aanensen; G N Pluister; A Tami; M Chlebowicz; C Glasner; A J Sabat; K Weist; O Heuer; A W Friedrich
Journal:  Euro Surveill       Date:  2014-12-11

6.  Accessory gene regulator (agr) dysfunction in Staphylococcus aureus bloodstream isolates from South Korean patients.

Authors:  Yong Pil Chong; Eun Sil Kim; Su-Jin Park; Ki-Ho Park; Tark Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Jin-Yong Jeong; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

7.  Risk factors for recurrence after Staphylococcus aureus bacteraemia. A retrospective matched case-control study.

Authors:  Timothy M Walker; Ian C J W Bowler; Philip Bejon
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

8.  Novel antibody-antibiotic conjugate eliminates intracellular S. aureus.

Authors:  Sophie M Lehar; Thomas Pillow; Min Xu; Leanna Staben; Kimberly K Kajihara; Richard Vandlen; Laura DePalatis; Helga Raab; Wouter L Hazenbos; J Hiroshi Morisaki; Janice Kim; Summer Park; Martine Darwish; Byoung-Chul Lee; Hilda Hernandez; Kelly M Loyet; Patrick Lupardus; Rina Fong; Donghong Yan; Cecile Chalouni; Elizabeth Luis; Yana Khalfin; Emile Plise; Jonathan Cheong; Joseph P Lyssikatos; Magnus Strandh; Klaus Koefoed; Peter S Andersen; John A Flygare; Man Wah Tan; Eric J Brown; Sanjeev Mariathasan
Journal:  Nature       Date:  2015-11-04       Impact factor: 49.962

9.  Nasal carriage as a source of agr-defective Staphylococcus aureus bacteremia.

Authors:  Davida S Smyth; Jared M Kafer; Gregory A Wasserman; Lili Velickovic; Barun Mathema; Robert S Holzman; Tiffany A Knipe; Karsten Becker; Christof von Eiff; Georg Peters; Liang Chen; Barry N Kreiswirth; Richard P Novick; Bo Shopsin
Journal:  J Infect Dis       Date:  2012-08-02       Impact factor: 5.226

10.  Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus.

Authors:  M C Enright; N P Day; C E Davies; S J Peacock; B G Spratt
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.